This analysis of the registry database DESCAR-T of more than 3,000 pediatric and adult patients with hematological malignancies who received CAR T cell therapy in France between 2018 and 2024 shows that only one person developed a secondary T cell malignancy following CAR T cell therapy.
- Remy Dulery
- Vincent Guiraud
- Roch Houot